Evolving Dynamics of Reimbursement and Post Listing Accessibility of High-Priced Innovative Medicines

Author(s)

Discussion Leader: Fei-Li Zhao, PharmD, MS, PhD, HEOR, BeiGene, Castle Hill, NSW, Australia
Discussants: Kun Zhao, MD, MHSci, PhD, Vanke School of Public Health, Tsinghua University, Beijing, China; Jiuhong Wu, PhD, PharmD, Beijing Health Economics Association, Beijing, China; Boxiong Tang, MD, PhD, BeiGene USA, Emeryville, CA, USA

PURPOSE:

This workshop will focus on the recent efforts and initiatives on the accessibility of patients to high-priced innovative medicines from multiple perspectives. The participants will gain a comprehensive understanding of the evolving dynamics of reimbursement assessment and access challenges post listing with a focus on China and complemented with international experiences.

DESCRIPTION:

Patient access to the life-saving and life-changing innovative medicines is challenging in many countries because of the limitation on the affordability and availability. Receiving national reimbursement subsidization is a big step forward to improve the affordability; however, following the listing, there still exist subsequent processes and barriers associated with the last mile of patient access to the treatment. The panel will discuss: 1) evolving dynamics of value assessment of high-priced innovative medicines; 2) efforts of improving the efficiency of reimbursement decisions with experiences from China; 3) the unique challenges of the last mile logistics of access post the reimbursement listing with case study from China; 4) the role industry is playing in improving patient access with collaborating with multiple stakeholders. The unique contribution of this workshop is covering both reimbursement assessment process as well as the post-listing accessibility issues. Dr Fei-Li Zhao will moderate the workshop and provide an overview of the accessibility issues of high-priced innovative medicines. Professor Kun Zhao will present recent development and her experience of assessing the value of high-cost innovative medicines from the standpoint of public payers. Professor Jiuhong Wu will use real world examples to elaborate the challenges and potential areas to improve for the post-listing accessibility. Professor Boxiong Tang will provide an industry perspective to address the topics. Discussions will start from China’s experiences, as well as other countries. We will engage all participants, especially those from Asian countries, to share their own country’s experiences and challenges through a round-table discussion.

Conference/Value in Health Info

2022-09, ISPOR Asia Pacific 2022, Virtual

Code

W13

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×